Epinephrine Autoinjector Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2024-2028

Epinephrine Autoinjector Market 2024-2028

The global epinephrine autoinjector market size is estimated to grow by USD 2.44 billion at a CAGR of 10.59% between 2023 and 2028. 

The companies operating in the market have been implementing different strategies to expand their product portfolio, especially over the last five years, which have significantly impacted the global epinephrine autoinjector market. They are undergoing different business strategies, such as M&A and technology partnerships, to increase their market presence and the sales of their product range. ALK Abello conducts clinical trials in order to prove Jext's efficacy equivalent to Viatriss EpiPen. Before Auvi-Q and Allerjects complete recall from the market, Sanofi engaged in various marketing strategies to increase its market share. Thus, companies are adopting various strategies to encourage end-users to use epinephrine autoinjectors, which will nullify the adverse impact of the high cost of these products. Such innovation and strategies for marketing by the companies will drive the growth of the market during the forecast period.

Technavio has segmented the market into Type, End-user, and Geography 

• The type is classified into 0.30gm, 0.15gm, and 0.50gm
• The end-users are classified into hospitals, clinics, and homecare
• The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.

What will be the size of the Epinephrine Autoinjector Market During the Forecast Period?

To learn more about this report, Request Free Sample

Epinephrine Autoinjector Market Segmentation by Type, End-user and Geography Analysis

Type Analysis 

0.30gm

The market share growth by the 0.30gm segment will be significant during the forecast period. The epinephrine auto-injectors market by 0.30gm dosage is expected to witness the highest growth due to the rise in volume sales of generic epinephrine autoinjectors. Amneal Pharmaceutical's generic Adrenaclick has already gained popularity after the sudden price hike by Viatris in the US market. 

Get a glance at the market contribution of various segments Download PDF Sample

The 0.30gm segment was the largest and was valued at USD 1,931.91 billion in 2018. The adoption of generic epinephrine autoinjectors is expected to increase further once Viatriss generic EpiPen gets launched in the market. In the European market, with the higher availability of different brands, Viatris's share may decrease, which may hamper its epinephrine auto-injectors market growth. Also, the gradual price hike of Viatris year-wise, after the periodic exit of its leading competitors from the market, led researchers from universities and emerging companies to focus on developing an alternative to EpiPen. Hence, with the latest developments, the growth of the epinephrine auto-injectors market by 0.30gm dosage is assured. These factors under the 0.30 gm dosage market segment will propel the growth of the epinephrine autoinjector market during the forecast period.

End-user Analysis 

Hospitals

Epinephrine autoinjectors are mostly used in outpatient units and emergency units of high-end hospitals and clinics in developed countries. Hospitals use them only for those patients who have appropriate medical insurance plans. In the US, there has been a consistent price hike of EpiPen for the last few years. Alternatives such as ampules or vials have become more popular. Viatriss EpiPen is the most commonly used device and has been reported to cause accidental injections on thumbs and other fingers, which are harmful. In contrast, Amneal Pharmaceuticals Inc. Adrenaclick is reported to be the most difficult to use. Hence, with the ease of availability of cheaper alternatives and usage issues of epinephrine autoinjectors, the global autoinjector market by hospitals is expected to show moderate growth during the forecast period.

Clinics

In developed countries, epinephrine autoinjectors are extensively used by individuals affected by allergies and vulnerable to anaphylactic shocks. Viatriss EpiPen is reimbursed by most medical insurance companies in the US and is a preferred epinephrine autoinjector by insured allergic individuals. Anaphylaxis can be fatal and requires immediate medication. The availability of products with advanced features helps patients reduce hospital visits and encourages self-administration of the drug, thereby promoting fast treatment. Moreover, many companies in the epinephrine auto-injectors market are launching new self-administration autoinjectors with extensive R&D procedures and are undergoing approvals from authorized bodies, such as the FDA. Companies are getting such approvals, especially for autoinjectors. Therefore, the global epinephrine autoinjector market is expected to show steep growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America was the leading revenue contributor to the epinephrine auto-injectors market in 2020, owing to high revenue generation in the US and Canadian markets. The lack of FDA approvals and strict FDA regulations for not considering any other generic epinephrine autoinjectors as an equivalent to Viatriss EpiPen eased the way for Viatriss monopoly in the booming US market. Furthermore, the epinephrine market in the US is projected to show significant growth owing to the higher adoption rates of generic epinephrine autoinjectors among individuals. With the launch of the generic EpiPen, the sales volume of epinephrine autoinjectors rose in the US market, which further drove the market growth.

In addition, R&D in developing autoinjectors in the market is expected to introduce varied types of autoinjectors in North America. For instance, in North America, researchers at university levels are striving hard to find an alternative to EpiPen. Also, due to favourable reimbursement policies, increasing partnerships between key companies, contract research organizations in emerging markets, and high expenditures in healthcare. Therefore, the above-mentioned factors are expected to drive the regional market during the forecast period.

Buy Full Report Now

Key Epinephrine Autoinjector Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 10 market companies, including:

Adamis Pharmaceuticals Corp. - The company offers epinephrine autoinjectors such as SYMJEPI 0.15mg, and SYMJEPI 0.3mg

• ALK Abello AS
• Amneal Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• BIOPROJET
• Crossject
• Halozyme Therapeutics Inc.
• kaleo Inc., Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Epinephrine Autoinjector Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Epinephrine Autoinjector Market Drivers

The rise in awareness of anaphylaxis and the availability of innovative epinephrine autoinjectors is notably driving the market growth. Global companies engage in awareness programs to educate people about epinephrine autoinjectors. For instance, Viatris is engaged in a multi-year alliance with Walt Disney Parks and Resorts to increase awareness regarding anaphylaxis. Epinephrine is the primary medication in the treatment line for anaphylaxis. Pharmaceutical companies are innovating technologically advanced epinephrine autoinjectors for the clinical and self-administration of anaphylaxis. Such advancements include making portable autoinjectors with innovative designs, devices with two auto-injectable doses in a single device, and devices made with a 0.1-mg dose of epinephrine for infants to 0.5 0.75-mg doses of epinephrine for adults.

Also, autoinjectors with better temperature stability and longer shelf life for epinephrine autoinjectors are also witnessing a global demand, especially for hospital and clinical applications. Thus, the rise in awareness through initiatives by key vendors, the availability of epinephrine autoinjectors in the market, and government initiatives to use therapeutics are expected to improve product sales during the forecast period. This, in turn, will positively impact the growth of the market during the forecast period.

Significant Epinephrine Autoinjector Market Trends

Frequent product launches due to government pressure on companies is an emerging trend shaping market growth. The US market is forecasted to witness a number of product launches during the forecast period due to the increased government pressure on the FDA to approve more generic products of epinephrine autoinjectors. For instance, after the price surge of Viatriss EpiPen, the US Governor, Margaret Wood Hassan, appealed to the FDA to consider and approve other alternatives to Viatriss EpiPen, including generic epinephrine autoinjectors. Companies such as Bausch Health and ALK Abello, which have substantial shares in the European market, may consider entering the US market after this US government initiative.

For instance, In March 2020, Teva Pharmaceutical Industries announced the commercial launch of the AJOVY in the prefilled YpsoMate 2.25 autoinjector in the German market. This is a clinical and self-administered autoinjector for adults with moderate to severe migraines. The product can administer 2.25 ml of the drug, and it is an anti-CGRP treatment for the prevention of migraines with monthly and quarterly dosing options. Hence, product launches and approvals for new products are expected to positively impact market growth during the forecast period.

Major Epinephrine Autoinjector Market Challenges

Product recalls and regulatory issues a significant challenges hindering market growth. The global epinephrine autoinjector market has continuously faced hindrances owing to periodic product recalls and regulatory issues over the years. The FDA approval process for epinephrine autoinjectors also has been slow, which paved the way for Viatriss monopoly. Additionally, after Sanofis exit, Viatris monopolized the US market, partially due to the FDAs limited approval of other products and partially because their only competitor, Impax Laboratories (now Amneal Pharmaceuticals), did not have an automated manufacturing facility of generic Adrenaclick supply.

Additionally, since the accuracy of epinephrine dose delivery is crucial during emergency anaphylactic shock, vendors are not left with any option other than a product recall. Hence, not many companies prefer to enter the market, which negatively influences the growth of the market during the forecast period.

Buy Now Full Report

Key Epinephrine Autoinjector Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Epinephrine Autoinjector Market Customer Landscape

Segment Overview

The epinephrine autoinjector market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Type Outlook
  • 0.30gm
  • 0.15gm
  • 0.50gm
• End-user Outlook
  • Hospitals
  • clinics
  • Homecare
• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW) 
    • Brazil
    • Argentina
    • Australia 

Epinephrine Autoinjector Market Scope
Report Coverage	Details
Page number	154
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 10.59%
Market Growth 2024-2028	USD 2.44 billion
Market structure	Concentrated
YoY growth 2023-2024(%)	8.78
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 46%
Key countries	US, Germany, UK, China, and Japan
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	Adamis Pharmaceuticals Corp., ALK Abello AS, Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., BIOPROJET, Crossject, Halozyme Therapeutics Inc., kaleo Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Epinephrine Autoinjector Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the epinephrine autoinjector market between 2024 and 2028
• Precise estimation of the epinephrine autoinjector market size and its contribution of the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of epinephrine autoinjector market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch